Bookmark and Share
BioAssay: AID 2152

TR-FRET-based biochemical high-throughput confirmation assay for inhibitors of Hepatitis C Virus (HCV) core protein dimerization.

Name: TR-FRET-based biochemical high-throughput confirmation assay for inhibitors of Hepatitis C Virus (HCV) core protein dimerization. ..more
_
   
 Tested Compounds
 Tested Compounds
All(2251)
 
 
Active(23)
 
 
Inactive(2228)
 
 
 Tested Substances
 Tested Substances
All(2251)
 
 
Active(23)
 
 
Inactive(2228)
 
 
AID: 2152
Data Source: The Scripps Research Institute Molecular Screening Center (HCVCORE_INH_HTRF_1536_3X%INH)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2009-11-20
Modify Date: 2010-06-15

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 23
Related Experiments
Show more
AIDNameTypeProbeComment
1899TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerizationScreening depositor-specified cross reference: Primary screen (HCV inhibitors).
1911Summary of probe development efforts to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerizationSummary depositor-specified cross reference: Summary AID.
2159TR-FRET-based biochemical high-throughput dose response assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization.Confirmatory depositor-specified cross reference
2488Late stage results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: TR-FRET-based biochemical dose response assay for HCV core inhibitorsConfirmatory depositor-specified cross reference
463085Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Luminescence-based biochemical AlphaScreen assay to identify inhibitors of HCV core dimerizationConfirmatory depositor-specified cross reference
485271Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: fluorescence-based cell-based quantitative PCR assay to identify inhibitors of HCV infectivityConfirmatory depositor-specified cross reference
485280Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Absorbance-based cell-based assay to identify compounds that are cytotoxic to Huh-7.5 cellsConfirmatory depositor-specified cross reference
624406Late stage results from the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Cell-based radioligand binding assay to determine the binding affinities for selected transporters, receptors, and GPCRsOther depositor-specified cross reference
651574Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Fluorescence-based cell-based Quantitative Polymerase Chain Reaction (QPCR) assay to identify inhibitors of HCV infectivity (2 timepoints)Other1 depositor-specified cross reference
651575Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Fluorescence-based cell-based Quantitative Polymerase Chain Reaction (QPCR) assay to identify inhibitors of HCV infectivityConfirmatory1 depositor-specified cross reference
651576Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Luminescence-based biochemical AlphaScreen assay to identify inhibitors of HCV core dimerization (%INH 15uM)Other1 depositor-specified cross reference
651577Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Luminescence-based biochemical dose response AlphaScreen assay to identify inhibitors of HCV core dimerizationConfirmatory1 depositor-specified cross reference
651583Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Absorbance-based cell-based assay to identify compounds that are cytotoxic to Huh-7.5 cellsConfirmatory depositor-specified cross reference
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: A.D. Strosberg, TSRI
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1-X01-MH085709-01
Grant Proposal PI: A.D. Strosberg, TSRI
External Assay ID: HCVCORE_INH_HTRF_1536_3X%INH

Name: TR-FRET-based biochemical high-throughput confirmation assay for inhibitors of Hepatitis C Virus (HCV) core protein dimerization.

Description:

The Hepatitis C virus (HCV) is a major cause of liver failure and hepatocellular cancer, with about 170 million people infected worldwide (1). The HCV has a small RNA genome that is directly translated by the infected host cell into a single precursor polyprotein that is processed by enzymatic cleavage into 10 proteins of diverse function. The most N-terminal 21kDa protein of this HCV polyprotein is the HCV core (C) protein, which is a highly basic, RNA-binding structural protein essential for assembly and packaging of the viral genome (2). Core protein is cleaved by a host peptidase and anchored to the host cell endoplasmic reticulum, where it undergoes further processing into its mature form (3). The N terminal portion of this mature C protein mediates viral assembly through homodimerization and formation of higher order complexes with viral RNA to form the nucleocapsid, while the hydrophobic C terminal interacts with envelope glycoproteins to form the infectious particle (4). The conserved nature of the HCV protein and absence of a vaccine to prevent HCV infection (5), along with studies demonstrating that C protein contributes to host cell oncogenesis (6), apoptosis inhibition (7), and suppression of host T cell responses (8), support a role for core protein as a major pathogenic component of HCV. The identification of specific inhibitors of HCV core dimerization will provide valuable tools for inhibiting HCV assembly without host cell effects.

References:

1. Hoofnagle, J.H., Course and outcome of hepatitis C. Hepatology, 2002. 36(5 Suppl 1): p. s21-s29.
2. Lin, C., Lindenbach, B.D., Pragai, B.M., McCourt, D.W., and Rice, C.M., Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J Virol, 1994. 68(8): p. 5063-73.
3. Moradpour, D. and Blum, H.E., A primer on the molecular virology of hepatitis C. Liver Int, 2004. 24(6): p. 519-25.
4. Majeau, N., Gagne, V., Boivin, A., Bolduc, M., Majeau, J.A., Ouellet, D., and Leclerc, D., The Nterminal half of the core protein of hepatitis C virus is sufficient for nucleocapsid formation. J Gen Virol, 2004. 85(Pt 4): p. 971-81.
5. Yang, J.P., Zhou, D., and Wong-Staal, F., Screening of small-molecule compounds as inhibitors of HCV entry. Methods Mol Biol, 2009. 510: p. 295-304.
6. Ray, R.B., Lagging, L.M., Meyer, K., and Ray, R., Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol, 1996. 70(7): p. 4438-43.
7. Marusawa, H., Hijikata, M., Chiba, T., and Shimotohno, K., Hepatitis C virus core protein inhibits Fasand tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol, 1999. 73(6): p.4713-20.
8. Large, M.K., Kittlesen, D.J., and Hahn, Y.S., Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol, 1999. 162(2): p. 931-8.

Keywords:

HCV, core protein, core 106, core, hepatitis, hepatitis C, RNA virus, protein-protein interaction,
dimerization, confirmation screen, HTS, high throughput screen, 1536, inhibitor, HTRF, TR-FRET, time resolved
fluorescence resonance energy transfer, fluorescence, Scripps, Scripps Florida, The Scripps Research Institute
Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Protocol
Assay Overview:
The purpose of this biochemical assay is to confirm activity of the top 2,500 most active compounds identified in
a previous set of experiments entitled, "TR-FRET-based primary biochemical high-throughput screening
assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization" (AID 1899). In this
assay, test compounds are incubated with N-terminally tagged GST-core106 and Flag-core106 peptides, followed
by addition of a Europium cryptate-tagged anti-GST antibody and a XL-665-tagged anti-Flag antibody.
Dimerization of the core106 peptides and subsequent antibody binding brings the antibody tags into close
proximity, allowing FRET from the Europium donor to the XL-665 acceptor, resulting in an increase in well
FRET. As designed, compounds that inhibit core106 dimerization will prevent the interaction of the tagged
antibodies, blocking the transfer of energy from Europium to XL-665, and thus inhibiting well FRET. Test
compounds were assayed in triplicate at a final nominal concentration of 5 micromolar.
Protocol Summary:
Prior to the start of the assay, 5 microliters of Assay Buffer (100 mM HEPES, 0.5 mM EDTA, 2.5 mM DTT, 200
mM Potassium Fluoride, 0.05% CHAPS, 0.05% BSA, pH 7.45, filtered at 0.22 micrometer) were dispensed into
columns 1 and 2 of 1536-well assay plates. The remaining 46 columns were filled with 2 microliters of Assay
Buffer supplemented with 225 ng/mL of Eu(K)-anti GST antibody and 42.5 nM of Flag-Core106. Next, 1
microliter of inhibition controls were dispensed into column 3 (12.5 micromolar unlabelled core106 protein,
100% inhibition), column 46 (200 nM core106 protein, 50% inhibition), and columns 4 to 45, 47 and 48 (Assay Buffer alone). Twenty-five nL of test compounds or DMSO alone (0.5% final concentration) were then added to the appropriate wells. Next, 2 microliters of Assay Buffer supplemented with 2.5 micrograms/mL XL665-anti FLAG antibody and 33.75 nM GST-Core106 were dispensed to columns 3 to 48. The assay plates were centrifuged for 30 seconds at 300g and incubated for 4 hours at 22.5 degrees Celsius. At the end of the incubation time, TR-FRET was measured by exciting the plates at 340 nm, and monitoring well fluorescence at 617 nm (Eu) and 671 nm (XL665) with the ViewLux microplate reader (PerkinElmer). All wells had a final volume of 5 microliters. The final reagent concentrations were 90 ng/mL Eu(K)-anti GST antibody, 1 microgram/mL XL665-anti FLAG, 17 nM Flag-Core106 and 13.5 nM GST-Core106. Final control concentrations were 2.5 micromolar and 40 nM for the 100% and 50% inhibition controls, respectively.
To normalize data, values measured from both fluorescence emission wavelengths were used to calculate a ratio for each well, according to the following mathematical expression:
Ratio = (I671nm / I617nm) x 10,000
Where:
I represents the measured fluorescence emission intensity at the enumerated wavelength in nanometers.
The percent inhibition for each compound is reported as the average and the standard deviation of three replicate wells, calculated as follows:
% Inhibition = ( 1 - ( ( Ratio_TestCompound - Median_Ratio_HighControl ) / ( Median_Ratio_LowControl - Median_Ratio_HighControl ) ) ) * 100
Where:
Test_Compound is defined as assay wells treated with test compound.
Negative_Control is defined as assay wells treated with DMSO.
Positive_Control is defined as assay wells treated with 1 micromolar of unlabelled Core106 protein.
Any compound that exhibited a percent inhibition greater than the hit cutoff calculated for the Primary screen was declared active. The reported PubChem Activity Score has been normalized to 100% of the highest observed inhibition value. % Inhibition values greater than or equal to 100 are reported as activity score 100. Negative % inhibition values are reported as activity score zero.
The reported Pubchem_Activity_Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.
The activity score range for active compounds is 100-51, for inactive 51-0.
List of Reagents:
GST-core106 (supplied by Assay Provider)
Flag-core106 (supplied by Assay Provider)
Unlabelled core106 peptide (supplied by Assay Provider)
Anti-Flag Antibody (XL-665 labeled) (Cisbio, part 61FG2XLB)
Anti-GST Antibody (Europium labeled) (Cisbio, part 61GSTKLB)
1536-well plates (Greiner, part 789175)
HEPES (Fisher Scientific, part BP299-500)
EDTA (Sigma, part E7889)
Potassium Fluoride (Sigma, part 402931)
Bovine Serum Albumin (Sigma, part A9647)
CHAPS (Sigma, part C5070)
DTT (Sigma, part 43815)
Comment
Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign‟s specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR. The MLSMR was not able to provide all compounds selected for testing in this AID.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Format: Biochemical
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Inhibition (5μM**)Normalized percent inhibition of the confirmation screen at a compound concentration of 5 micromolar.Float%
2Standard DeviationStandard deviation of the confirmation assay derived from the normalized percent inhibition of the triplicate data for each compound.Float

** Test Concentration.
Additional Information
Grant Number: 1-X01-MH085709-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: